Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 16, Issue 2, Pages 239-249Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.16.2.239
Keywords
angiogenesis inhibitor; medullary thyroid cancer; non-small cell tung cancer; tyrosine kinase inhibitor; vandetanib; ZD6474
Categories
Ask authors/readers for more resources
Vandetanib (ZD6474; ZACTIMA(TM), AstraZeneca) is a once-daily, orally available agent with potential for use in a number of solid tumor types. Vandetanib targets key signaling pathways in cancer by inhibiting VEGFR-dependent tumor angiogenesis, and EGFR- and RET-dependent tumor cell proliferation and survival. Phase I studies showed vandetanib to be generally well tolerated at doses of <= 300 mg/day, with a pharmacokinetic profile that supports once-daily oral administration. Phase II evaluation of vandetanib in patients with advanced refractory NSCLC has demonstrated improvements in progression-free survival both as monotherapy (versus gefitinib) and in combination with docetaxel (versus docetaxel alone). These positive outcomes have led to the initiation of Phase III trials of vandetanib in advanced NSCLC. Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available